Carboplatin
Showing 1 - 25 of 3,600
Head and Neck Squamous Cell Carcinoma Trial in United States (TAK-676, Carboplatin, 5-FU)
Completed
- Head and Neck Squamous Cell Carcinoma
- TAK-676
- +8 more
-
Shreveport, Louisiana
- +3 more
Oct 3, 2023
Endometrial Carcinoma Trial in Sohag (Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin)
Not yet recruiting
- Endometrial Carcinoma
-
Sohag, EgyptSohag university Hospital
Oct 25, 2023
Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer Trial in Toronto (RP-6306, Carboplatin, Paclitaxel)
Not yet recruiting
- Recurrent Ovarian Cancer
- +3 more
- RP-6306
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Oct 25, 2023
Prostate Cancer Trial in Houston (ADI-PEG 20, Cabazitaxel, Carboplatin)
Not yet recruiting
- Prostate Cancer
- ADI-PEG 20
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 16, 2023
Merkel Cell Carcinoma Trial in Milano, Siena, Verona (Pembrolizumab, Etoposide, Cisplatin or Carboplatin)
Not yet recruiting
- Merkel Cell Carcinoma
- Pembrolizumab, Etoposide, Cisplatin or Carboplatin
-
Milano, Italy
- +2 more
Oct 10, 2023
Advanced Epithelial Ovarian Cancer Trial in Cairo (Carboplatin/paclitaxel)
Completed
- Advanced Epithelial Ovarian Cancer
-
Cairo, EgyptPharmacology and toxicology department, Faculty of Pharmacy, Cai
Jul 19, 2023
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,
Not yet recruiting
- HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
- PERT-IJS plus trastuzumab, carboplatin and docetaxel
- Perjeta plus trastuzumab, carboplatin and docetaxel
- (no location specified)
Sep 21, 2023
Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)
Not yet recruiting
- Recurrent Ovarian Cancer
- CPI-0209
- carboplatin
-
Pittsburgh, PennsylvaniaMagee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023
Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)
Recruiting
- Breast Cancer
- Neoadjuvant
- pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
-
Wuhan, Hubei, China
- +1 more
Aug 18, 2023
Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)
Not yet recruiting
- Ovarian Cancer
- (no location specified)
Jul 20, 2023
HNSCC, Oral Cancer, PD-1 Trial in Guangzhou (Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses,
Recruiting
- HNSCC
- +2 more
- Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
- Perbolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
-
Guangzhou, Guangdong, ChinaSun yat-sen memorial hospital
Aug 6, 2023
Metastatic Triple-Negative Breast Cancer Trial in Charlotte (Trilaciclib, Pembrolizumab, Gemcitabine)
Not yet recruiting
- Metastatic Triple-Negative Breast Cancer
- Trilaciclib
- +3 more
-
Charlotte, North CarolinaLevine Cancer Institute
Aug 31, 2023
Urinary Bladder Cancer Trial in Assiut (Carboplatin-Gemcitabine Cisplatin-Gemcitabine)
Recruiting
- Urinary Bladder Cancer
- Carboplatin-Gemcitabine Cisplatin-Gemcitabine
-
Assiut, EgyptAssiutU
Apr 22, 2023
Locally Advanced Breast Cancer, Chemo Effect Trial in Beijing (inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP)
Recruiting
- Locally Advanced Breast Cancer
- Chemotherapy Effect
- inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
-
Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Feb 28, 2023
Head and Neck Squamous Cell Carcinoma, Oral Cancer Trial in Guangzhou (Tirelizumab ,+Carboplatin+albumin-bound paclitaxel)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Oral Cancer
- Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
-
Guangzhou, Guangdong, ChinaSun yat-sun memorial hospital
Jul 10, 2023
Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer Trial in Carmel, Indianapolis
Not yet recruiting
- Metastatic Breast Cancer
- +2 more
- Carboplatin
- Tocilizumab
-
Carmel, Indiana
- +2 more
Apr 27, 2023
Advanced Solid Tumors Trial in Netherlands, Spain (Debio 0123, Carboplatin)
Recruiting
- Advanced Solid Tumors
- Debio 0123
- Carboplatin
-
Groningen, Netherlands
- +3 more
Jan 27, 2023
Ovarian Cancer Trial in San Diego (VS-6063, Paclitaxel, Carboplatin)
Recruiting
- Ovarian Cancer
- VS-6063
- +2 more
-
San Diego, CaliforniaUniversity of California San Diego
Feb 1, 2023
Triple-negative Breast Cancer Trial (Taxane and Carboplatin, Short-term Sintilimab, Surgery)
Not yet recruiting
- Triple-negative Breast Cancer
- Taxane and Carboplatin
- +2 more
- (no location specified)
Apr 25, 2023
NSCLC Trial in Seoul (Lazertinib/Pemetrexed/Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Mar 23, 2023
Adult Solid Tumor Trial in Chicago (Carboplatin, Laboratory Biomarker Analysis, Paclitaxel)
Active, not recruiting
- Adult Solid Neoplasm
- Carboplatin
- +4 more
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Jan 25, 2023
NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer Metastatic
- Atezolizumab
- +5 more
- (no location specified)
Jan 18, 2023
Lung Cancer Trial in Tampa, Columbus (Carboplatin, Paclitaxel, AZD1775)
Active, not recruiting
- Lung Cancer
- Carboplatin
- +2 more
-
Tampa, Florida
- +1 more
Feb 2, 2023
Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom
Active, not recruiting
- Triple Negative Metastatic Breast Cancer
- +3 more
- KU-0059436 (AZD2281)(PARP inhibitor)
- +3 more
-
Brussels, Belgium
- +3 more
Dec 19, 2022
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Denmark, Norway, Sweden (KAND567, Carboplatin)
Recruiting
- Epithelial Ovarian Cancer
- +2 more
- KAND567
- Carboplatin
-
Odense, Denmark
- +3 more
Oct 16, 2023